CHMP Endorses Expanded Use of Amgen's Repatha®

The European Medicines Agency's CHMP has given a positive opinion on Repatha® by Amgen, a PCSK9 inhibitor, recommending its use for cardiovascular risk reduction in adults at high risk for atherosclerotic cardiovascular disease, but without prior heart attacks or strokes. This recommendation stems from the VESALIUS-CV Phase 3 trial involving over 12,000 patients, highlighting Repatha's potential to significantly reduce major adverse cardiovascular events (MACE) when combined with statins or other LDL-C lowering treatments.

Amgen's chief medical officer, Paul Burton, noted the persistent challenge in reaching recommended LDL-C levels in high-risk patients despite available therapies. Repatha, already approved in the EU for patients with ASCVD, showed new promise in reducing first-time heart attacks, reinforcing its potential impact on redefining cardiovascular patient care.

Pending the European Commission's approval, the expanded indication could significantly influence treatment protocols in Europe, addressing unmet needs in cardiovascular health management.